GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer

Saturday, GSK plc GSK announced overall survival (OS) results from Part 1 and progression-free survival (PFS) results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial of Jemperli (dostarlimab) for primary advanced or recurrent endometrial cancer, paving the way for a potential label…#gskplc #gsk #rubyengoten6 #fda #jemperli #jemperlipluszejula #zejula
Source: Reuters: Health - Category: Consumer Health News Source Type: news